MedKoo Cat#: 127157 | Name: WJ-39
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WJ-39 is an orally active aldose reductase (AR) inhibitor.

Chemical Structure

WJ-39
WJ-39
CAS#3009908-95-3

Theoretical Analysis

MedKoo Cat#: 127157

Name: WJ-39

CAS#: 3009908-95-3

Chemical Formula: C19H14Cl2KNO4

Exact Mass: 428.9937

Molecular Weight: 430.32

Elemental Analysis: C, 53.03; H, 3.28; Cl, 16.48; K, 9.09; N, 3.26; O, 14.87

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
100mg USD 1,250.00 2 Weeks
1g USD 4,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
WJ-39; WJ39; WJ 39
IUPAC/Chemical Name
potassium 2-(3-(2,3-dichlorobenzyl)-6-methoxy-4-oxoquinolin-1(4H)-yl)acetate
InChi Key
KOVHOMQLMHEHRB-UHFFFAOYSA-M
InChi Code
InChI=1S/C19H15Cl2NO4.K/c1-26-13-5-6-16-14(8-13)19(25)12(9-22(16)10-17(23)24)7-11-3-2-4-15(20)18(11)21;/h2-6,8-9H,7,10H2,1H3,(H,23,24);/q;+1/p-1
SMILES Code
COC1=CC=C(N(CC(O[K])=O)C=C(CC2=CC=CC(Cl)=C2Cl)C3=O)C3=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 430.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhou X, Liu Z, Ying K, Wang H, Liu P, Ji X, Chi T, Zou L, Wang S, He Z. WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling. Oxid Med Cell Longev. 2020 May 30;2020:7950457. doi: 10.1155/2020/7950457. PMID: 32566101; PMCID: PMC7277034. 2: Yang L, Xu L, Hao X, Song Z, Zhang X, Liu P, Wang S, He Z, Zou L. An aldose reductase inhibitor, WJ-39, ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling. Eur J Pharmacol. 2024 Mar 15;967:176376. doi: 10.1016/j.ejphar.2024.176376. Epub 2024 Feb 8. PMID: 38336014.